Obesity independently contributes to erectile dysfunction through multiple pathways
What is the recommended dosage schedule for switching from semaglutide (GLP-1 receptor agonist) 0.5mg to tirzepatide (dual GIP and GLP-1 receptor agonist)?
According to the study, these questionnaires may fail to capture important elements of a patients clinical and social history
This aims to enhance access to GLP-1 medications for individuals enrolled in Medicare and Medicaid
Recent research has shown that combining the actions of GLP-1 and GIP can offer a novel approach to treating obesity and diabetes, leading to the development of dual agonists like Tirzepatide
Glucose uptake assay Glucose uptake was monitored with the fluorescent deoxyglucose analogue 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) (Thermo Fisher Scientific, San Jose, CA, USA) 47